Status:
RECRUITING
Remote Ischemic Preconditioning in Type 2 Diabetic Patients Undergoing CABG
Lead Sponsor:
Muğla Sıtkı Koçman University
Conditions:
Diabetes Mellitus
Coronary Artery Bypass
Eligibility:
All Genders
45-85 years
Phase:
NA
Brief Summary
This randomized, double-blind, prospective clinical trial aims to investigate the effect of remote ischemic preconditioning (RIPC) on myocardial protection in patients with type 2 diabetes mellitus un...
Eligibility Criteria
Inclusion
- Diagnosed with type 2 diabetes mellitus and receiving medical treatment
- Scheduled for isolated elective coronary artery bypass graft (CABG) surgery
- American Society of Anesthesiologists (ASA) physical status class III or IV
- Age between 40 and 85 years
Exclusion
- Emergency CABG surgery Reoperation (revision surgery) Left ventricular ejection fraction (LVEF) \< 40% History of cardiac arrest or cardiogenic shock Pregnancy Clinically significant peripheral arterial disease affecting the upper limbs Hepatic dysfunction (bilirubin \> 20 μmol/L or INR \> 2.0) Renal failure (eGFR \< 20 mL/min/1.73 m²) Ongoing treatment with glibenclamide or nicorandil (agents known to interfere with ischemic preconditioning mechanisms) Asthma
Key Trial Info
Start Date :
May 26 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06977230
Start Date
May 26 2025
End Date
September 15 2025
Last Update
June 18 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mugla Training and Research Hospital
Muğla, Turkey (Türkiye), 48000
2
Mugla Training and Research Hospital
Muğla, Turkey (Türkiye)